Brand Recall Hub

Nitro Recalls in Canada

52 recalls found for Nitro. Data sourced from Health Canada, CFIA, and Transport Canada. Updated daily.

52 Nitro Recalls

Health Products Type I
2026-04-15

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization (DIN)

Product safety

View recall details →

Health Products Type I
2026-04-14

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization (DIN)

Product safety

View recall details →

Health Products Type I
2026-03-19

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization (DIN)

Product safety

View recall details →

Health Products Type I
2026-03-12

Cream Chargers: Sold for Inhalation Without Market Authorization (DIN)

Product safety

View recall details →

Health Products Type I
2025-12-09

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization (DIN)

Product safety

View recall details →

Health Products Type I
2025-11-28

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization (DIN)

Product safety

View recall details →

Other
2025-11-20

Health Canada warns consumers not to inhale nitrous oxide, also known as laughing gas, recreationally

Product safety - Unauthorized product

View recall details →

Health Products Type I
2025-11-10

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization (DIN)

Product safety

View recall details →

Health Products Type I
2025-11-05

Nitrous Oxide Chargers: Sold for Inhalation Without Market Authorization (DIN)

Unauthorized product

View recall details →

Health Products Type I
2025-07-16

Mylan-Cinacalcet: Affected lots exceed the established acceptable intake limit for N-nitroso-cinacalcet.

Product quality

View recall details →

Health Products Type I
2025-07-04

PMS-Methylphenidate CR 10 mg capsule; exceed the acceptable intake limit for N-nitroso-methylphenidate

Product quality

View recall details →

Health Products Type I
2025-07-03

RIVA-Fluoxetine 10 mg capsule; may exceed the interim acceptable intake limit for N-nitroso-fluoxetine

Product quality

View recall details →

Health Products Type I
2025-06-30

PMS-Fluoxetine 10 mg capsule; may exceed the interim acceptable intake limit for N-nitroso-fluoxetine

Product quality

View recall details →

Health Products Type I
2025-06-30

PRO-Fluoxetine 10 mg capsule; may exceed the interim acceptable intake limit for N-nitroso-fluoxetine

Product quality

View recall details →

Health Products Type I
2025-04-29

RIVA-FLUOXETINE: Affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.

Product quality

View recall details →

Health Products Type I
2025-04-28

PMS-FLUOXETINE: Affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.

Product quality

View recall details →

Health Products Type I
2025-04-28

PRO-FLUOXETINE: Affected lots exceed the interim acceptable intake limit for N-nitroso-fluoxetine.

Product quality

View recall details →

Health Products Type II
2025-04-11

NRA-Quetiapine XR: Some lots exceed the intake limit of N-nitroso-desalkyl-quetiapine (NDAQ)

Product quality

View recall details →

Health Products Type II
2025-02-27

Sensipar (30mg, 60mg, 90mg): Levels of N-nitroso-cinacalcet exceeding the established acceptable intake (AI) limits in affected lots.

Product safety

View recall details →

Health Products Type I
2025-01-31

APO-QUETIAPINE XR - May exceed the established acceptable intake limit for N-nitroso-desalkyl-quetiapine (NNAP).

Product quality

View recall details →

Health Products Type I
2025-01-07

QUETIAPINE XR : Affected lots may exceed the established acceptable intake limit for N-nitroso-desalkyl-quetiapine (NNAP)

Product quality

View recall details →

Health Products Type I
2024-12-30

PMS-CINACALCET: Affected lots may exceed the established acceptable intake limit for N-nitroso-cinacalcet.

Product safety

View recall details →

Health Products Type I
2024-12-05

BETAHISTINE: Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-betahistine.

Product safety

View recall details →

Health Products Type I
2024-12-04

TEVA-Betahistine Tablets: Affected lots exceed or may exceed the interim acceptable intake limit for N-nitroso-betahistine.

Product safety

View recall details →

Health Products Type II
2024-11-06

Pregnancy Multivitamin, Pregnancy Multivitamin Folic 5: Affected lots exceed the acceptable intake limit for N-nitroso-folic acid

Product safety

View recall details →

Medical Devices Type II
2024-07-05

Nitro™ Glide Knee Walker

Performance

View recall details →

Health Products Type I
2024-05-16

Sanis Health Duloxetine 60 mg Capsule; Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)

Product quality

View recall details →

Health Products Type I
2024-04-17

PMS-Duloxetine 30 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)

Product quality

View recall details →

Health Products Type I
2024-04-17

PMS-Duloxetine 60 mg: Exceeds acceptable interim intake limit for N-nitroso-duloxetine (NDLX)

Product quality

View recall details →

Health Products Type II
2024-03-12

FOLIC ACID 1MG - Affected lots exceed or may exceed the acceptable intake limit for N-nitroso-folic acid.

Product quality

View recall details →

Showing 30 of 52 recalls. View all →